Credit Suisse disclosed AC Immune (UNKNOWN:ACIU), hiking its price target to $18.00 earlier today
- Updated: October 18, 2016
Reporting a possible upside of 0.18%, Credit Suisse bumped up the target of AC Immune (UNKNOWN:ACIU) to $18.00
Yesterday AC Immune (UNKNOWN:ACIU) traded 5.27% higher at $15.23. The company’s 50-day moving average is $16.17 and its 200-day moving average is $16.17. The last stock close price is down -6.04% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 252,119 shares of the stock were exchanged, down from an average trading volume of 521,300
See Chart Below
AC Immune has a 52 week low of $13.01 and a one year high of $19.97 with a price-earnings ratio of 32.81 ACIU’s total market value is presently $0.
Brief Synopsis About AC Immune (UNKNOWN:ACIU)
AC Immune Ltd is a Switzerland-based company engaged in the medical biotechnology sector. It develops treatments for Alzheimer's and other neurodegenerative diseases, such as Down syndrome, glaucoma and Parkinson's, and focuses on producing therapeutic and diagnostic product candidates, using SupraAntigen and Morphomer technology platforms. The Company's pipeline includes Crenezumab, ACI-24, Anti-Tau antibody, Morphomer Tau, Tau-PET imaging agent, Morphomer Abeta and Morphomer alpha-syn, among others.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.